Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Blinatumomab/inotuzumab-ozogamicin

Various toxicities, lack of efficay and drug resistance

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Prazmo A, et al. Relapse/Refractory Paediatric B-ALL Case with CD19- Phenotype Switching Indicating the Importance of Appropriate Diagnostic Approach and Targeted Treatment Adjustment-Case Report. International Journal of Molecular Sciences 24: No. 17, Jan 2023. Available from: URL: https://doi.org/10.3390/ijms241713322 Prazmo A, et al. Relapse/Refractory Paediatric B-ALL Case with CD19- Phenotype Switching Indicating the Importance of Appropriate Diagnostic Approach and Targeted Treatment Adjustment-Case Report. International Journal of Molecular Sciences 24: No. 17, Jan 2023. Available from: URL: https://​doi.​org/​10.​3390/​ijms241713322
Metadaten
Titel
Blinatumomab/inotuzumab-ozogamicin
Various toxicities, lack of efficay and drug resistance
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54772-6

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Metronidazole

Case report

Alendronic-acid